IGOLD study. A subset of 225 from this cohort were also used for sequence analysis of PTCHD1. Details of these samples are published elsewhere (36). 167 unrelated patients diagnosed with ADHD were recruited through the Department of Psychiatry at the Hospital for Sick Children, Toronto. Microarray data from controls included 1,123 (M=623, F=500) controls recruited from northern Germany as a part of the PopGen project, 1,234 (M=586, F=648) healthy controls of European origin recruited from the province of Ontario, Canada, 1,287 (M=383, F=904) controls from the Study of Addiction: Genetics and Environment (SAGE), 1,320 (M=589, F=1320) controls from Children’s Hospital of Philadelphia (CHOP), 4783 (M=2460, F=2323) controls were recruited by the Wellcome Trust Case Control Consortium, 440 (M=158, F=282) controls were recruited by The Centre of Addiction and Mental Health (CAMH) and GlaxoSmithKline (GSK), and 59 (M=30, F=29) from the Centre d’Etude Polymorphisme Humaine (CEPH) HapMap controls (total N=5,023). We sequenced more than 650 Ontario controls obtained from The Centre for Applied Genomics (TCAG) and The Centre for Addiction and Mental Health (CAMH). Details of all samples included in the study are summarized in table S5. Institutional ethical review board approval (CAMH, HSC, CHOP and all other collaborating institutions) was
